Repurposing old drugs as antiviral agents for coronaviruses

Repurposing old drugs as antiviral agents for coronaviruses

Background: New therapeutic options to address the ongoing coronavirus disease 2019 (COVID-19) pandemic are urgently needed. One possible strategy is the repurposing of existing drugs approved for other indications as antiviral agents for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)....

Full description

Bibliographic Details
Main Authors:	Cheng-Wei Yang, Tzu-Ting Peng, Hsing-Yu Hsu, Yue-Zhi Lee, Szu-Huei Wu, Wen-Hsing Lin, Yi-Yu Ke, Tsu-An Hsu, Teng-Kuang Yeh, Wen-Zheng Huang, Jiunn-Horng Lin, Huey-Kang Sytwu, Chiung-Tong Chen, Shiow-Ju Lee
Format:	Article
Language:	English
Published:	Elsevier 2020-08-01
Series:	Biomedical Journal
Subjects:	Coronavirus COVID-19 Cytopathic effect HCoV-OC43 SARS-CoV-2 Drug repurpose
Online Access:	http://www.sciencedirect.com/science/article/pii/S2319417020300664

Similar Items

Inhibition of SARS-CoV-2 by Highly Potent Broad-Spectrum Anti-Coronaviral Tylophorine-Based Derivatives
by: Cheng-Wei Yang, et al.
Published: (2020-12-01)

Phylogenetic characteristics of Non-SARS human coronavirus in southern Taiwan, 2012–2013
by: Hsuan-Chen Wang, et al.
Published: (2023-08-01)

Apoptosis Enhances the Replication of Human Coronavirus OC43
by: Sony Maharjan, et al.
Published: (2021-11-01)

Human Coronavirus Infections in Israel: Epidemiology, Clinical Symptoms and Summer Seasonality of HCoV-HKU1
by: Nehemya Friedman, et al.
Published: (2018-09-01)

Endemic Human Coronavirus-Specific Nasal Immunoglobulin A and Serum Immunoglobulin G Dynamics in Lower Respiratory Tract Infections
by: Ferdyansyah Sechan, et al.
Published: (2024-01-01)

The FDA-approved drug nitazoxanide is a potent inhibitor of human seasonal coronaviruses acting at postentry level: effect on the viral spike glycoprotein
by: Sara Piacentini, et al.
Published: (2023-08-01)

Coronaviruses in Children, Greece
by: Anna Papa, et al.
Published: (2007-06-01)

Influenza-like illness symptoms due to endemic human coronavirus reinfections are not influenced by the length of the interval separating reinfections
by: Ferdyansyah Sechan, et al.
Published: (2024-03-01)

A Novel Method to Reduce ELISA Serial Dilution Assay Workload Applied to SARS-CoV-2 and Seasonal HCoVs
by: David Pattinson, et al.
Published: (2022-03-01)

Previous exposure to common coronavirus HCoV-NL63 is associated with reduced COVID-19 severity in patients from Cape Town, South Africa
by: Lida C. Lesmes-Rodríguez, et al.
Published: (2023-02-01)

Photodynamic Inactivation of Human Coronaviruses
by: Brett A. Duguay, et al.
Published: (2022-01-01)

Atypical Antibody Dynamics During Human Coronavirus HKU1 Infections
by: Ferdyansyah Sechan, et al.
Published: (2022-04-01)

Repurposing carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2
by: Haiyan Yan, et al.
Published: (2021-09-01)

Montelukast Inhibits HCoV-OC43 Infection as a Viral Inactivator
by: Yongkang Chen, et al.
Published: (2022-04-01)

The Impacts of 'Coronavirus' and Probable Outcomes: A South Asian Perspective
by: Muhammad Jamaluddin, et al.
Published: (2020-04-01)

Heparan Sulfate and Enoxaparin Interact at the Interface of the Spike Protein of HCoV-229E but Not with HCoV-OC43
by: Virginia Fuochi, et al.
Published: (2023-03-01)

Co-circulation of Four Human Coronaviruses (HCoVs) in Queensland Children with Acute Respiratory Tract Illnesses in 2004
by: Theo P. Sloots, et al.
Published: (2012-04-01)

Robust Evaluation of Ultraviolet-C Sensitivity for SARS-CoV-2 and Surrogate Coronaviruses
by: S. J. Boegel, et al.
Published: (2021-10-01)

Epigallocatechin Gallate (EGCG), a Green Tea Polyphenol, Reduces Coronavirus Replication in a Mouse Model
by: Rackhyun Park, et al.
Published: (2021-12-01)

Antiviral Activity of Contemporary Contact Lens Care Solutions against Two Human Seasonal Coronavirus Strains
by: Christiane Lourenco Nogueira, et al.
Published: (2022-04-01)

Synthesis of Novel 1-Oxo-2,3,4-trisubstituted Tetrahydroisoquinoline Derivatives, Bearing Other Heterocyclic Moieties and Comparative Preliminary Study of Anti-Coronavirus Activity of Selected Compounds
by: Meglena I. Kandinska, et al.
Published: (2023-02-01)

Genomic Analysis of 15 Human Coronaviruses OC43 (HCoV-OC43s) Circulating in France from 2001 to 2013 Reveals a High Intra-Specific Diversity with New Recombinant Genotypes
by: Nathalie Kin, et al.
Published: (2015-05-01)

Genetic Characterisation and Comparison of Three Human Coronaviruses (HKU1, OC43, 229E) from Patients and Bovine Coronavirus (BCoV) from Cattle with Respiratory Disease in Slovenia
by: Monika Jevšnik Virant, et al.
Published: (2021-04-01)

Optimizing human coronavirus OC43 growth and titration
by: Christopher Savoie, et al.
Published: (2022-07-01)

High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients
by: Uri Greenbaum, et al.
Published: (2021-04-01)

Inhibition by components of Glycyrrhiza uralensis of 3CLpro and HCoV-OC43 proliferation
by: Jang Hoon Kim, et al.
Published: (2023-12-01)

Kurarinone Inhibits HCoV-OC43 Infection by Impairing the Virus-Induced Autophagic Flux in MRC-5 Human Lung Cells
by: Jung Sun Min, et al.
Published: (2020-07-01)

Erythromycin Estolate Is a Potent Inhibitor Against HCoV-OC43 by Directly Inactivating the Virus Particle
by: Xiaohuan Wang, et al.
Published: (2022-07-01)

The cholesterol metabolite 27-hydroxycholesterol inhibits SARS-CoV-2 and is markedly decreased in COVID-19 patients
by: Alessandro Marcello, et al.
Published: (2020-09-01)

Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study
by: Li Guo, et al.
Published: (2021-01-01)

A nano-luciferase expressing human coronavirus OC43 for countermeasure development
by: Meghan V. Diefenbacher, et al.
Published: (2024-01-01)

Auraptene Has Antiviral Activity against Human Coronavirus OC43 in MRC-5 Cells
by: Jung Sun Min, et al.
Published: (2023-06-01)

SURTO NOSOCOMIAL DE BETACORONAVÍRUS EM SÃO PAULO APÓS REDUÇÃO DE CASOS DE COVID-19
by: Tânia do Socorro Souza Chaves, et al.
Published: (2023-10-01)

Cross-Immunization Against Respiratory Coronaviruses May Protect Children From SARS-CoV2: More Than a Simple Hypothesis?
by: Pier Paolo Piccaluga, et al.
Published: (2021-01-01)

Establishment of a screening platform based on human coronavirus OC43 for the identification of microbial natural products with antiviral activity
by: Blanca Martínez-Arribas, et al.
Published: (2024-01-01)

Evaluating the Impact of gRNA SNPs in CasRx Activity for Reducing Viral RNA in HCoV-OC43
by: Cathryn Michelle Mayes, et al.
Published: (2022-06-01)

A high-throughput drug screening strategy against coronaviruses
by: Jia Liu, et al.
Published: (2021-02-01)

Surface Inactivation of Human Coronavirus by MACOMA™ UVA-TiO<sub>2</sub> Coupled Photocatalytic Disinfection System
by: Timsy Uppal, et al.
Published: (2022-06-01)

Restriction of SARS-CoV-2 replication by receptor transporter protein 4 (RTP4)
by: Ramanjit Kaur, et al.
Published: (2023-08-01)

Betacoronaviruses SARS-CoV-2 and HCoV-OC43 infections in IGROV-1 cell line require aryl hydrocarbon receptor
by: Meisam Yousefi, et al.
Published: (2023-12-01)